Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study
The lancet. HIV | 29 Nov 2015
JH Elliott, JH McMahon, CC Chang, SA Lee, W Hartogensis, N Bumpus, R Savic, J Roney, R Hoh, A Solomon, M Piatak, RJ Gorelick, J Lifson, P Bacchetti, SG Deeks and SR Lewin
In vitro, disulfiram activated HIV transcription in a primary T-cell model of HIV latency and in a pilot clinical study increased plasma HIV RNA in individuals with adequate drug exposure. We assessed the effect of disulfiram on HIV transcription in a dose-escalation study.
* Data courtesy of Altmetric.com